LAUREATE IN THE SCIENTIST OF THE YEAR CATEGORY
FOR DISCOVERIES IN THE AREA OF DOPAMINE SYSTEM AND TRACE AMINE-ASSOCIATED RECEPTORS, WHICH ENABLED NEW APPROACHES TO DEVELOPING PHARMACEUTICALS FOR TREATING BRAIN DISORDERS
RAUL GAINETDINOV
Candidate of Sciences in Medicine
Director, Institute of Translational Biomedicine (since 2015), Head of Laboratory of Neurobiology and Molecular Pharmacology, Head of Research, Pirogov Clinic of High Medical Technologies, St. Petersburg State University
ABOUT THE LAUREATE
According to the World Health Organization, 24 million people worldwide are diagnosed with schizophrenia, which means that one in 300 people are affected by this condition. About 5 percent of global adult population suffer from depression, and of those, 75 percent get no treatment for their condition whatsoever.
Parkinson's disease is a neurodegenerative condition that affects the motor system and causes mental disorders, sleep abnormalities, pain and other symptoms. There is no known cure for PD at the moment, but its symptoms can be alleviated by using a range of therapies and pharmaceuticals. According to statistical data, the worldwide prevalence of Parkinson's disease has doubled in the past 25 years.
Raul Gainetdinov heads groundbreaking research in the area of experimental pharmacology for brain disorders, aimed at developing treatment for schizophrenia, depression, Parkinson’s disease and attention-deficit/hyperactivity disorder (ADHD) in children.
Raul Gainetdinov is awarded the VYZOV Prize in Scientist of the Year category for discovering brand-new pharmaceutical approaches to the treatment of brain disorders. He has set a new goalpost for pharmacology with regard to dopamine system and trace amine-associated receptors, enabling brand-new approaches to developing pharmaceuticals for treating brain disorders.
Raul Gainetdinov works in the field of experimental pharmacology for brain diseases, using genetically modified animals as models for studying human diseases. He has authored more than 340 scientific articles (including publications in Science, Nature, Cell, PNAS, etc.), and holds 13 international patents. He has an h-index of 91, with his research having been cited more than 29,000 times. Mr. Gainetdinov has served as Chair of the NC-IUPHAR Subcommittee for Dopamine Receptors since 2013. The Web of Science (WoS) has included him in its Highly Cited Researchers list in the area of pharmacology and toxicology, which features the 0.1 percent of the world’s most cited scientists. In December 2022, Russian President Vladimir Putin personally commended Raul Gainetdinov for his accomplishments.